| 摘要 |
The invention relates to a pharmaceutical composition comprising a polynucleotide and at least 2 % (weight/volume), preferably 2 to 10 %, of a nonionic copolymer of formula (I) OH(CH2CH2O)a(CH(CH3)CH2O)b(CH2CH2O)cH, in which a, b, and c are such that the polyoxypropylene portion has a molecular weight of between 1450 and 2050, and the polyoxyethylene portions constitute between 75 and 85 % (weight : weight) of the copolymer. The composition is preferably free of cationic lipid or of sodium phosphate. The copolymer is intended to improve the transfer of the polynucleotide into, or the expression of the polynucleotide in, eukaryotic cells. A typical example of a copolymer corresponding to formula (I) is F68. A composition according to the invention is in particular useful in the gene therapy, vaccination and immunotherapy fields.
|
